Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements about fosfomycin/fosfomycin tromethamine and oral use are consistent with label excerpts, but the response does not address or is not fully assessable against key labeled safety/administration/indication content; one potentially imprecise statement (“still fosfomycin”) is only indirectly supported by the label excerpt showing conversion to free acid fosfomycin.
Category Scores
Accurate Statements
Fosfomycin tromethamine is a salt form of fosfomycin used in some oral products.
Section 12/Clinical Pharmacology excerpt describes Fosfomycin tromethamine and that after oral administration it is converted to the free acid, fosfomycin (indicating a salt form relationship).
Fosfomycin tromethamine is used for oral use.
Section 2 indicates Fosfomycin Tromethamine is taken with or without food and should be mixed with water before ingesting; Section 12 describes absorption following oral administration.
Fosfomycin may be described with different salt forms depending on the product and route.
Not explicitly stated in provided excerpts; however, the provided label text clearly uses “Fosfomycin Tromethamine” and distinguishes it from “fosfomycin” (free acid) after conversion. (This supports that naming/forms can differ.)
Unsupported Statements
The generic name is fosfomycin.
Provided label excerpt is for Fosfomycin Tromethamine granules; no excerpt provided states that the generic name is simply “fosfomycin.”
Fosfomycin is often written as fosfomycin tromethamine for the oral formulation.
No label excerpt provided states this wording convention.
The active antibacterial ingredient in fosfomycin tromethamine is still fosfomycin.
Label excerpt states fosfomycin tromethamine is converted to the free acid, fosfomycin, and that fosfomycin is the active component; the statement is broadly consistent but “still” is imprecise and not directly worded in the excerpt.
Fosfomycin Tromethamine is used for oral use.
Supported (so not truly unsupported); this entry not applicable. (Retained list only for other unsupported items.)
Contradictions
Important Omissions
Labeled indication specifics: uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis, and not for pyelonephritis/perinephric abscess.
Importance:
Moderate
Key dosage/administration instructions: single sachet single dose for women 18+; mix with water; do not take in dry form; do not use more than one single dose to treat a single episode.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response is largely about naming/form and does not include key labeled indication and administration limitations (single-dose guidance and mixing with water). Omission of these can lead to misunderstanding of proper labeled use even though the naming statements themselves are not clearly unsafe.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several identity/naming claims are not directly supported by the provided label excerpts, and the response omits material labeled indication and administration/dose-limit details.
Suggested Improvement
Restrict naming claims to what the label excerpt supports (fosfomycin tromethamine converted to fosfomycin) and include the labeled indication (acute cystitis in women; susceptible E. coli/Enterococcus faecalis; not pyelonephritis) plus administration guidance (mix with water; single-dose; do not use dry; do not exceed one single dose per episode).